Results
1 -
10 of
10Zhang Xin, Lv Peng-Cheng, Li Dong-Dong, Zhang Wei-Ming, Zhu Hai-Liang.
Navigating into the chemical space between MGCD0103 and SAHA: novel histone deacetylase inhibitors as a promising lead, Med. Chem. Commun., 2015 Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents, Journal of Hematology & Oncology Role of Epigenetic Modulation for the Treatment of Sarcoma, Current Treatment Options in Oncology Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells, Cancer Chemotherapy and Pharmacology Application of Hematological Toxicity Modeling in Clinical Development of Abexinostat (S-78454, PCI-24781), A New Histone Deacetylase Inhibitor, Pharmaceutical Research Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients, Investigational New Drugs Abexinostat, Reactions Weekly The histone deacetylase inhibitor PCI-24781 as a putative radiosensitizer in pediatric glioblastoma cell lines, Cancer Cell International Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression, Breast Cancer Research